|
Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry. |
|
|
|
|
Consulting or Advisory Role - Amgen; Amgen; Celgene; Janssen; Karyopharm Therapeutics; Takeda |
Research Funding - Celgene (Inst) |
Travel, Accommodations, Expenses - Celgene; Karyopharm Therapeutics |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - McKesson |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; EMD Serono; Sandoz; Takeda |
|
|
Consulting or Advisory Role - Janssen; Takeda |
|
|
Consulting or Advisory Role - Celgene |
Speakers' Bureau - Celgene; Janssen |
|
|
Speakers' Bureau - Celgene; Janssen Oncology; Millennium; Pharmacyclics |
|
|
Consulting or Advisory Role - Celgene |
Speakers' Bureau - Myriad Genetics |
Travel, Accommodations, Expenses - Dava Oncology |
|
|
Consulting or Advisory Role - Celgene |
|
|
Consulting or Advisory Role - Celgene; EveryFit; Janssen |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen Biotech; Takeda |
Research Funding - Cellectar (Inst); Janssen Biotech (Inst); Pharmacyclics (Inst); Phosplatin Therapeutics (Inst) |
Travel, Accommodations, Expenses - Amgen; Novartis; Takeda |
|
|
|
Travel, Accommodations, Expenses - Takeda |
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Celgene; Pimera; Takeda |
Research Funding - Amgen; Celgene; Daiichi Sankyo; Janssen; Prothena; Takeda |
|
|
|
Stock and Other Ownership Interests - Celgene |
Patents, Royalties, Other Intellectual Property - Patent on a Graphic tool with applications including the characterization of the use of oncology therapies over time. US patent 7,495,673 B1.; Patent pending on a heat map prediction matrix tool in Multiple Myeloma predicting survival. (Inst) |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
Honoraria - Amgen; Celgene; Janssen; Takeda |
Speakers' Bureau - Amgen; Celgene; Janssen; Takeda |
|
|
|
|
|
Consulting or Advisory Role - Celgene; Takeda |
Research Funding - Celgene; Prothena; Takeda |